C4 Therapeutics (CCCC) Operating Margin (2019 - 2026)
C4 Therapeutics (CCCC) recorded quarterly Operating Margin of 451.64% in Q1 2026, down 114.96% quarter-over-quarter from 210.1% in Q4 2025, and down 4871.0% on a YoY basis from 9.47% in Q1 2025.
C4 Therapeutics (CCCC) Operating Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' Operating Margin history runs 8 years deep, the most recent figure standing at 451.64% for Q1 2026.
- In Q1 2026, Operating Margin fell 4871.0% year-over-year to 451.64%; the TTM figure through Mar 2026 stood at 326.56% (down 3358.0% YoY), while the FY2025 annual figure was 320.53%, up 1561.0% from the prior year.
- Operating Margin was 451.64% for Q1 2026 at C4 Therapeutics, down from 210.1% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 178.59% in Q2 2024 to a low of 1410.21% in Q2 2023.
- Historically, Operating Margin has averaged 598.03% across 5 years, with a median of 440.99% in 2025.
- The sharpest annual moves came in 2022 and 2024: Operating Margin sank 126575 bps in 2022, then soared 123162 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 1341.73% in 2022, then gained by 14 bps to 1147.72% in 2023, then jumped by 37 bps to 728.39% in 2024, then surged by 71 bps to 210.1% in 2025, then sank by 115 bps to 451.64% in 2026.
- The last three Operating Margin figures came in at 451.64% (Q1 2026), 210.1% (Q4 2025), and 306.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | C4 Therapeutics | 520.69 Mn | 285.02 Mn | - | -451.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -451.64% |
| Dec 31, 2025 | -210.10% |
| Sep 30, 2025 | -306.43% |
| Jun 30, 2025 | -440.99% |
| Mar 31, 2025 | -402.93% |
| Dec 31, 2024 | -728.39% |
| Sep 30, 2024 | -183.86% |
| Jun 30, 2024 | -178.59% |
| Mar 31, 2024 | -1,060.18% |
| Dec 31, 2023 | -1,147.72% |
| Sep 30, 2023 | -251.16% |
| Jun 30, 2023 | -1,410.21% |
| Mar 31, 2023 | -963.77% |
| Dec 31, 2022 | -1,341.73% |
| Sep 30, 2022 | -481.02% |
| Jun 30, 2022 | -197.95% |
| Mar 31, 2022 | -409.84% |
| Dec 31, 2021 | -75.98% |
| Sep 30, 2021 | -285.34% |
| Jun 30, 2021 | -226.11% |